Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 5.9% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics (NASDAQ: NTLA) is a biotechnology company focused on developing CRISPR/Cas9-based therapies for genetic diseases. The company has recently received positive news related to regulatory approvals and analyst upgrades.

Why is Intellia Therapeutics, Inc. going up?

NTLA stock is up 5.9% on Apr 13, 2026 18:51

• Intellia Therapeutics (NTLA) saw a significant increase of 14.2% in its stock price today.
• The rise in stock price is linked to the FDA lifting clinical holds on Intellia's MAGNITUDE trials, which has provided regulatory clarity and bolstered investor confidence.
• An analyst upgrade from Jones Trading further boosted optimism about Intellia, emphasizing the potential of its gene editing programs for conditions like ATTR amyloidosis and HAE.
• The market is reflecting expectations for future growth for Intellia, as evidenced by its high Price/Sales ratio, indicating positive outlook on the company's prospects in the gene editing industry.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Intellia (NASDAQ: NTLA) revises bylaws on shareholder notices and federal forums

Intellia Therapeutics, Inc. has amended its bylaws, effective April 7, 2026, to allow shareholders to correct "facially apparent deficiencies" in timely notices for director nominations or other proposals. The company is now required to notify shareholders of such errors. Additionally, the updated bylaws designate U.S. federal district courts as the exclusive forum for complaints under the Securities Act of 1933 or the Securities Exchange Act of 1934, unless Intellia agrees otherwise in writing.

https://www.stocktitan.net/sec-filings/NTLA/8-k-intellia-therapeutics-inc-reports-material-event-7cb23d22e718.html

Assessing Intellia Therapeutics (NTLA) Valuation After FDA Clears MAGNITUDE Trials And Analyst Upgrade

Intellia Therapeutics (NTLA) has seen a resurgence in investor interest following the FDA's clearance of its MAGNITUDE trials and an analyst upgrade, leading to significant short-term stock gains. Despite trading at a high price-to-sales ratio compared to industry averages, analysts view the stock as undervalued, with a narrative fair value of $25.29 against a current price of $13.55, driven by the expansion of its gene editing programs for conditions like ATTR amyloidosis and HAE. The future valuation, however, significantly depends on successful late-stage trial execution, real-world safety, and navigating competitive and reimbursement challenges.

https://www.sahmcapital.com/news/content/assessing-intellia-therapeutics-ntla-valuation-after-fda-clears-magnitude-trials-and-analyst-upgrade-2026-04-08

Why Intellia Therapeutics (NTLA) Is Up 14.2% After FDA Lifts MAGNITUDE Trial Holds and Upgrade

Intellia Therapeutics (NTLA) saw a 14.2% stock price increase after the FDA lifted clinical holds on its MAGNITUDE and MAGNITUDE-2 ATTR trials, following a patient death deemed unrelated to the treatment. This regulatory clarity, along with an upgrade from Jones Trading, has bolstered investor confidence in Intellia's CRISPR pipeline despite ongoing losses and competition. The company's investment narrative now focuses on the upcoming HAELO Phase 3 data and potential commercial uptake of its one-time gene therapies.

https://www.sahmcapital.com/news/content/why-intellia-therapeutics-ntla-is-up-142-after-fda-lifts-magnitude-trial-holds-and-upgrade-2026-04-07

Assessing Intellia Therapeutics (NTLA) Valuation After FDA Clears MAGNITUDE Trials And Analyst Upgrade

Intellia Therapeutics (NTLA) is drawing renewed attention after the FDA lifted clinical holds on its MAGNITUDE trials, following a determination that a patient death was unlikely related to its therapy. The stock has seen recent rebounds, with a 1-year total shareholder return of 115.76%, contrasting a multi-year decline. While analysts view Intellia as significantly undervalued with a fair value of $25.29, its high Price/Sales ratio of 23.7x suggests the market might already be pricing in future growth, indicating mixed signals for investors.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/assessing-intellia-therapeutics-ntla-valuation-after-fda-cle

Why Intellia Therapeutics (NTLA) Is Up 14.2% After FDA Lifts MAGNITUDE Trial Holds and Upgrade

Intellia Therapeutics (NTLA) shares rose 14.2% after the FDA lifted clinical holds on its MAGNITUDE and MAGNITUDE-2 ATTR trials, providing renewed regulatory clarity. This decision followed an upgrade from Jones Trading and has positively impacted Intellia's investment narrative, particularly concerning its CRISPR pipeline's resilience. The company now looks forward to key HAELO Phase 3 data, reinforcing the potential for its one-time CRISPR interventions, despite ongoing concerns about long-term safety and commercial viability.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/why-intellia-therapeutics-ntla-is-up-142-after-fda-lifts-mag

Trending Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.2% Today

Intellia Therapeutics, Inc. Price History

26.01.2026 - NTLA Stock was up 10.7%

• After revealing its Q4 earnings, NTLA stock saw a noteworthy increase in value, surprising analysts who had forecast a marginal decrease in both EPS and revenue compared to the previous year.
• The FDA's decision to remove a clinical hold on Intellia's gene-editing medication had a favorable impact on the stock's performance, hinting at potential competitiveness in the rare disease pharmaceuticals market.
• Intellia's upcoming involvement in investor conferences scheduled for March 2026 also played a role in boosting market confidence, as investors displayed keen interest in the company's strategic vision and growth prospects.

31.02.2026 - NTLA Stock was up 5.2%

• Despite receiving a "Hold" rating from most brokerages, Intellia Therapeutics experienced a significant uptrend after being upgraded to a "strong-buy" by Truist Financial.
• The gene editing sector, including Intellia Therapeutics, faced a downtrend, possibly influencing the stock price initially.
• Intellia Therapeutics' recent strong earnings report, surpassing expectations, likely boosted investor confidence in its performance.
• The internal reshuffling of Vanguard's holdings, resulting in share disaggregation, may have caused some uncertainty but did not have a direct impact on the stock movement.

05.02.2026 - NTLA Stock was down 5.1%

• The bearish movement in NTLA stock today could be attributed to profit-taking by investors after a recent surge in the stock price.
• Actions impacting GLP-1 compounders by the FDA might have raised concerns about regulatory scrutiny in the biotech sector, negatively affecting NTLA's stock.
• Despite positive clinical news and increased stake by Vanguard Group Inc., the overall market sentiment towards biotech companies like Intellia might have been affected by the uncertainty surrounding FDA actions and regulatory compliance.
• Insider sales at Intellia, the company's pre-revenue status, and negative margins could have also contributed to the bearish sentiment among investors.

05.02.2026 - NTLA Stock was down 5.1%

• Despite recent positive developments, such as analyst upgrades, strong financial results, and progress with its Phase 3 trial after regulatory hurdles were resolved, Intellia Therapeutics saw a decline in its stock price.
• The market response may have been influenced by the company's decision to expand its At-The-Market offering program to $1.04 billion, which could potentially lead to dilution of existing shares and impact shareholder value.
• Concerns regarding the company's financial performance, such as negative margins and a high valuation, despite advancements in its pipeline and clinical work, might have unsettled investors.
• The divergence in opinions among analysts and the uncertainty surrounding Intellia's path to profitability likely contributed to the negative market sentiment, even amidst positive strides in its therapeutic initiatives.

03.02.2026 - NTLA Stock was down 5.1%

• The stock price of Intellia Therapeutics plummeted despite recent positive developments and analyst upgrades, indicating a possible case of "buy the rumor, sell the news" behavior among investors.
• The FDA's decision to lift the clinical hold on the MAGNITUDE Phase 3 trial for a key therapy was initially seen as a positive development, but concerns over the safety and efficacy of the treatment may have led to the market's negative reaction.
• The company's decision to increase its At-The-Market offering program to $1.04 billion could have also contributed to the bearish sentiment, signaling potential dilution of existing shares and impacting shareholder value.
• Overall, the market movement suggests that investors may be exercising caution and reevaluating their positions in Intellia Therapeutics amidst a mix of positive news and financial decisions by the company.

24.01.2026 - NTLA Stock was up 5.7%

• The development of an investigational gene editing therapy for hereditary transthyretin (ATTR) amyloidosis through CRISPR/Cas9 technology has likely spurred investor optimism and interest in Intellia Therapeutics.
• Encouraging reduction in harmful protein production observed in early clinical trial findings could pave the way for advancements in treating genetic disorders, potentially enhancing the company's standing and stock performance.
• Noteworthy institutional investments, such as those from Jupiter Asset Management Ltd. amounting to $23.52 million, signal increasing confidence in Intellia Therapeutics' future prospects and may have influenced the recent positive market trend.
• Anticipation surrounding an imminent conference call to discuss financial results and business updates could be fueling positive investor sentiment and driving up the stock price.

19.02.2026 - NTLA Stock was down 5.4%

• Farallon Capital Management LLC acquired a significant number of shares in NTLA, indicating confidence in the company's potential.
• Despite reporting better-than-expected earnings and surpassing analyst revenue estimates, company insiders have been selling shares in the last ninety days.
• The increased holdings by institutional investors may have contributed to the downward pressure on NTLA's stock price.
• The bearish movement could be a result of profit-taking by insiders or concerns about the sustainability of NTLA's recent positive performance.

25.02.2026 - NTLA Stock was up 5.3%

• The rise in NTLA's stock price might be due to positive sentiment from AI models suggesting short-term strength and the adoption of potential institutional trading strategies.
• Despite recent selling by Hudson Bay Capital Management LP and company insiders, the stock surpassed Q3 revenue and EPS estimates, indicating solid fundamentals.
• A possible securities class action lawsuit alleging lack of disclosure on the inefficiency of the NTLA-3001 program initially led to a stock price decline, but investors appear hopeful about the company's future prospects.
• In summary, the surge in Intellia Therapeutics' stock price today could be driven by a blend of positive sentiment, exceeding financial expectations, and potential institutional trading strategies.

27.01.2026 - NTLA Stock was up 5.2%

• Intellia Therapeutics (NTLA) reported a Q4 loss of $0.83 per share, but exceeded revenue estimates, indicating strong potential for revenue growth.
• The positive momentum was driven by an earnings beat, promising trial data for hereditary angioedema, and the release of an FDA clinical hold, boosting investor confidence in the company's pipeline.
• The stock's valuation narrative is mixed, with discussions about high current multiples but substantial undervaluation based on future revenue potential, emphasizing the significance of upcoming milestones such as the Phase 3 HAELO trial for future growth.
• Despite recent share price increases, the company's three-year return is negative, signaling investor optimism about Intellia Therapeutics' long-term prospects despite some short-term obstacles.

13.03.2026 - NTLA Stock was up 5.9%

• Intellia Therapeutics (NTLA) saw a significant increase of 14.2% in its stock price today.
• The rise in stock price is linked to the FDA lifting clinical holds on Intellia's MAGNITUDE trials, which has provided regulatory clarity and bolstered investor confidence.
• An analyst upgrade from Jones Trading further boosted optimism about Intellia, emphasizing the potential of its gene editing programs for conditions like ATTR amyloidosis and HAE.
• The market is reflecting expectations for future growth for Intellia, as evidenced by its high Price/Sales ratio, indicating positive outlook on the company's prospects in the gene editing industry.

02.02.2026 - NTLA Stock was up 5.6%

• Intellia Therapeutics observed a significant uptrend in trading today, driven by a variety of positive developments:
• The company posted strong Q4 2025 earnings and revenue, surpassing expectations and demonstrating robust financial performance.
• Analysts at Chardan Capital reiterated a "Buy" rating with a target price of $26, showcasing confidence in the company's growth trajectory.
• Investor optimism has been fueled by Intellia's focus on its lonvo-z candidate for HAE, with upcoming Phase 3 data and a BLA submission.
• The FDA's removal of the clinical hold on Intellia's MAGNITUDE-2 trial for its gene-editing programs has further bolstered positive sentiment surrounding the stock.

11.02.2026 - NTLA Stock was down 7.9%

• Despite promising long-term data for its HAE candidate and FDA approval for its ATTR-CM therapy, concerns persist among investors regarding ongoing losses, liver safety issues, and lengthy path to profitability.
• The participation in the Leerink Global Healthcare Conference could give the company a chance to address investor worries and clarify its strategic outlook.
• The stock price surge following the FDA's removal of clinical holds on its gene-editing drug nex-z reflects investor confidence, although safety concerns and high costs of gene-editing therapies remain.
• NTLA is deemed undervalued compared to its fair value estimate, indicating that investors, despite recent positive developments, are still wary of potential clinical hurdles or slow therapy adoption that could impact future performance.